Jetblack Corp publicized today the details of their, very first of its type, wellness product under making.
The latest identification of the CB1 and CB2 cannabinoid receptors along with their endogenous lipid ligands has led to an increase in researches inspecting the endocannabinoid system and its regulatory operations dealing with ailments and health.
The company is developing a product which aids in cleansing the CB1 and CB2 receptors and the endocannabinoid system so that marijuana, along with its cannabinoids, is more efficient.
A person who consumes marijuana daily experiences a lessening in its effectiveness relative to a person who uses it less often.
As stated by the New Frontier Data, 2017 statistics display how nearly 12% of the adults in the United States use marijuana every day, whereas 11% of U.S. adults consume marijuana on a weekly basis. Last year, the total sale, in the United States, of legal marijuana amounted to more than 9 billion dollars.
Research related to the endocannabinoid system is in its early stages, the system is in the process of being studies. The company believes that the product may also prove to be advantageous to non-cannabis users since they are now familiar with how the endocannabinoid system plays a significant part in our health. Daniel A. Goldin, the chief executive officer of Jetblack Corp, stated how this is the reason they have called it the wellness product from the very start. He added how they were excited to put the finishing touches on its development, initiate trials, together with its development and production.
He said: “We believe it is truly a unique product and may benefit people in a variety of ways. I am not aware of another product like it on the market.”